Avecho Biotechnology Limited provided an update on the progress of its Australian Phase I pharmacokinetic (PK) study designed to characterise the absorption profile of cannabidiol (CBD) from its CBD soft-gel product, announcing enrolment of the first healthy volunteers. The Study will support Avecho's strategic focus of developing pharmaceutical CBD products that leverage its proprietary TPM formulations. The Study will assess Avecho's 75 mg CBD soft-gel product, which has been developed and manufactured by Catalent Inc. at its facility in Florida, US. Subjects in the study will receive two separate doses over a period of two weeks, with dosing due to begin in early October. The Study has been designed to form a key piece of a future regulatory submission, as well as to inform ongoing research and development for Avecho's CBD product portfolio and potential commercial partnerships in this space.